Table 1 Patients’ characteristics in the sorafenib group and the HAIC group

 Male/Female

27 / 6

28 / 7

Mean age (years)

70.9 ± 9.1

72.0 ± 7.0

 HCV / HBV / NBNC

20 / 4 / 10

21 / 3 / 11

 Ablation/TACE+TAE/None

1/20/12

2/24/9

 A / B / C

2 / 13 /18

2 /14 /19

 II/IIIA/IIIB/IIIC/IVA/IVB

14/3/7/1/3/5

15/2/6/2/4/6

 5 / 6 / 7

10 /19 /4

20 / 11 / 4

 yes / no

22 / 11

21 / 14

 yes / no

8 / 25

10 / 25

 yes / no

10 / 23

5 / 30

AFP (ng/mL) ^a

216.7 (5–161,160)

67.3 (2–281,600)

DCP (mAU/mL) ^a

1068 (14–272,000)

335 (12–99,800)